Sep. 11 at 8:43 PM
Leerink⬆️
$MAZE PT to
$34 from
$28, reit'd at an OP/said MZE782 data exceeded its expys/support a pot'l best-in-class profile.
&
BTIG⬆️the PT on
$MAZE to
$37 from
$30, reit'd Buy/said, Phase 1 HV data of MZE782 reported today exceeded expectations and support best-in-class potential, showing urinary Phe excretion increases of 39-fold with a 960mg single dose and 42-fold with 240mg BID (mgmt. previously guided to >10-fold and >15-fold increases in PKU and CKD, respectively).
$AGIO $BMRN $PTCT $TVTX
BTIG went on to say:
